Just saw that Sam Raha officially took over as CEO at Myriad Genetics back in April. Interesting move - the guy was their COO before this, and apparently he's been there since late 2023. Seems like they fast-tracked him through the ranks pretty quickly. His background is in diagnostics and genomics, previously ran that division at Agilent, so at least he knows the industry. The outgoing CEO Paul Diaz is staying on as a consultant for a year, which is a pretty smooth transition setup. Meanwhile Mark Verratti got bumped up from Chief Commercial Officer to COO. The board chair was pretty enthusiastic about Sam Raha's appointment, talking about his strategic vision and operational expertise. Not sure how the market reacted to the leadership shake-up, but on paper it looks like they're trying to keep things stable while bringing in fresh leadership. Worth keeping an eye on how Sam Raha navigates the next few quarters for them.